{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-030014","form_type":"8-K","ticker":"PBYI","cik":"0001401667","company_name":"PUMA BIOTECHNOLOGY, INC.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.909360+00:00","generated_at":"2026-06-08T23:47:45.147937+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Puma Biotechnology Q3 2023 net income $5.8M, reverses prior-year loss; revenue $56.1M","bullets":["Product revenue net $51.6M (down 5% YoY from $54.3M); total revenue $56.1M.","GAAP net income $5.8M ($0.12/diluted) vs net loss $0.4M in Q3 2022.","Non-GAAP adjusted net income $8.3M ($0.17/diluted) vs $2.5M prior year.","Cash and securities $85.0M; net cash from operations $10.7M in Q3.","Q4 product revenue guidance $56-59M; FDA accepted IND for alisertib, granted orphan drug designation for SCLC."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-030014","json":"https://secwatch.observer/filing/0001437749-23-030014.json","markdown":"https://secwatch.observer/filing/0001437749-23-030014.md","text":"https://secwatch.observer/filing/0001437749-23-030014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401667/000143774923030014/0001437749-23-030014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401667/000143774923030014/pbyi20231030_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T23:47:45.147937+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f2ecc81b91f8b547aaa8c2f940106ff6f35ed7f0","claim":"PUMA BIOTECHNOLOGY, INC. reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"On November 2, 2023, Puma Biotechnology, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401667/000143774923030014/0001437749-23-030014-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}